37
Participants
Start Date
August 17, 2020
Primary Completion Date
May 6, 2023
Study Completion Date
May 6, 2023
Camrelizumab
200mg, intravenous drip administration, d1, every 3 weeks.
S-1
Oral, d1-14, every 3 weeks.
Oxaliplatin
130mg/m² intravenous drip administration, d1, every 3 weeks(For patients with liver and/or para-aortic lymph node metastasis).
Paclitaxel
Intraperitoneal paclitaxel 20 mg/m² and intravenous paclitaxel 50 mg/m² on days 1 and 8, every 3 weeks(For patients with peritoneal metastasis ).
First Hospital of Jilin University, Changchun
Quan Wang
OTHER